Depo-Provera Does Not Cause Ovarian Cysts or Fibroids—In Fact, It Protects Against Them
Depo-Provera (medroxyprogesterone acetate) does not cause ovarian cysts or uterine fibroids; substantial evidence demonstrates it actually reduces the risk of both conditions.
Ovarian Cysts
Depo-Provera provides significant protection against ovarian cysts. A large multi-center study found that DMPA use was associated with a 35% decreased risk of ovarian cancer overall (OR 0.65,95% CI 0.50-0.85), with a statistically significant dose-response relationship showing greater protection with longer duration of use 1. This protective effect is biologically plausible given DMPA's mechanism of suppressing ovulation, which reduces the formation of functional ovarian cysts.
The FDA label for Depo-Provera does not list ovarian cyst formation as an adverse effect 2. When evaluating bleeding irregularities in DMPA users, guidelines recommend considering "new pathologic uterine conditions (e.g., polyps or fibroids)" as potential underlying causes—but this refers to pre-existing or coincidental conditions, not drug-induced pathology 3.
Uterine Fibroids
The evidence strongly indicates that Depo-Provera protects against uterine fibroids rather than causing them:
- A large cross-sectional study of 1,696 young African American women found that ever use of DMPA was associated with a 20% decreased risk of prevalent fibroids (adjusted RR 0.8,95% CI 0.6-0.9) 4
- Women who used DMPA for more than 4 years had a 50% reduction in fibroid risk (adjusted RR 0.5,95% CI 0.3-0.8) 4
- This protective effect persisted for up to 8 years after discontinuation 4
Therapeutic Use for Existing Fibroids
When fibroids are already present, DMPA can be used therapeutically:
- A pilot study showed that DMPA treatment reduced mean uterine volume by 48% and fibroid volume by 33% over 6 months 5
- 70% of women with symptomatic fibroids noticed improvement in bleeding patterns, and 30% became amenorrheic 5
Clinical Implications
If a patient on Depo-Provera develops ovarian cysts or fibroids, these are coincidental findings, not drug-induced. The timing is important: these conditions are common in reproductive-age women (fibroids affect up to 70% of women by menopause), so their discovery during DMPA use reflects background prevalence, not causation.
Important Caveats
- DMPA commonly causes irregular bleeding patterns (amenorrhea in 55% at 1 year, 68% at 2 years) 2. This can mask symptoms of fibroids, potentially delaying diagnosis of pre-existing conditions
- If abnormal bleeding persists or is severe in a DMPA user, rule out organic pathology including fibroids 2
- The FDA label warns about meningioma risk with long-term use, but does not mention ovarian cysts or fibroids as adverse effects 2
Bottom line: Reassure patients that Depo-Provera does not cause these conditions and may actually provide long-term protection against both ovarian cysts and uterine fibroids.